Literature DB >> 17722079

What is the potential for overdiagnosis of heparin-induced thrombocytopenia?

Gregory K Lo1, Christopher S Sigouin, Theodore E Warkentin.   

Abstract

Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize platelet factor 4//heparin (PF4/H) complexes. According to the "iceberg model," only a subset of anti-PF4/heparin antibodies of IgG class evincing strong platelet-activating properties cause clinical HIT. Since many centers rely predominantly on an anti-PF4/polyanion enzyme-immunoassay (EIA) to diagnose HIT, we estimated the potential for overdiagnosis when only this single test is available. We examined a database of 100 patients in whom the probability of HIT had been estimated using a clinical scoring system (4Ts), and where patients underwent systematic testing for HIT antibodies using three assays: the platelet serotonin release assay (SRA), an "in-house" EIA that detects IgG anti-PF4/heparin antibodies (EIA-IgG), and a commercial EIA that detects anti-PF4/polyanion antibodies of all three immunoglobulin classes (EIA-GTI). Whereas 16 of 100 patients fulfilled a "classic" definition of HIT (intermediate/high probability plus strong platelet-activating anti-PF4/heparin IgG antibodies), an additional 16 patients fulfilled a "liberal" definition in which any investigated patient (irrespective of the pretest probability) who had a positive EIA-GTI was considered to have HIT. The clinical features of these 16 additional patients--including generally weak antibodies and low risk for thrombosis--suggest underlying non-HIT explanations for thrombocytopenia. Patients with a positive SRA generally corresponded to those with intermediate or high pretest probability of HIT who also had strong EIA-GTI reactivity (>1.20 OD units). We conclude there is the potential to overdiagnose HIT by approximately 100% if any positive EIA is considered to "confirm" the diagnosis of HIT irrespective of the clinical scenario.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722079     DOI: 10.1002/ajh.21032

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  34 in total

1.  The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia.

Authors:  Gang Zheng; Michael B Streiff; Clifford M Takemoto; Jennifer Bynum; Elise Gelwan; Jayesh Jani; Danielle Judge; Thomas S Kickler
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.

Authors:  Janice McFarland; Andrew Lochowicz; Richard Aster; Bryan Chappell; Brian Curtis
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 3.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).

Authors:  M V Joglekar; P M Quintana Diez; S Marcus; R Qi; B Espinasse; M R Wiesner; E Pempe; J Liu; D M Monroe; G M Arepally
Journal:  Thromb Haemost       Date:  2012-02-08       Impact factor: 5.249

5.  Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia.

Authors:  Ming Y Lim; Joyce Foster; Angela Rourk; Charles S Greenberg
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

6.  A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis.

Authors:  Anand Padmanabhan; Curtis G Jones; Brian R Curtis; Daniel W Bougie; Mia J Sullivan; Namrata Peswani; Janice G McFarland; Daniel Eastwood; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2016-02-19       Impact factor: 9.410

7.  A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Thromb Haemost       Date:  2015-07-16       Impact factor: 5.249

8.  Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients.

Authors:  Vanessa Nellen; Irmela Sulzer; Gabriela Barizzi; Bernhard Lämmle; Lorenzo Alberio
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 9.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

10.  A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.

Authors:  Karen M Curzio; A Cheng-Lai; V Kheyfets; M Sinnet; H H Billett
Journal:  J Thromb Thrombolysis       Date:  2008-09-25       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.